HEMAB THERAPEUTICS H (COAG) is drawing unusual attention today. Our newswire has captured 1 story on COAG across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
COAG stock fell 5.77% to $51.77 in afternoon trading on Friday. The decline came despite a recent price target increase from Wedbush and other positive analyst coverage. The stock opened with a 3.2% gap up from the previous close but reversed sharply throughout the session, reaching a low of $51.77.
Hemab Therapeutics opened at $56.70, reflecting a positive gap from the prior close of $54.94. However, the stock quickly reversed course and declined throughout the day, closing at $51.77 at 2:05 PM ET. The session saw a volume of 0.1M shares, below the average for the stock. The move followed Wedbush’s recent upgrade of the price target to $64 from $55 and similar upgrades from HC Wainwright & Co. and Jefferies. Despite this analyst activity, the stock’s performance was weighed down by the company’s Q2 earnings report, which showed an EPS of $(0.80), missing the estimated $(0.52). Hemab also announced the presentation of clinical and preclinical data at the International Society on Thrombosis and Haemostasis 2026 Congress.
The stock has traded between $23.00 and $55.42 over the past 52 weeks. The recent intraday move saw the stock print two fresh 52-week highs and two fresh 52-week lows on August 17. Insider transactions show Ra Capital Management, L.P. has made two purchases totaling $1.8M in the past 90 days, with the most recent filing on June 17. These transactions suggest continued confidence from major stakeholders.
Investors should monitor the stock ahead of any upcoming corporate developments or additional analyst commentary. No earnings date was provided in the data. Coverage breadth and price target changes from key analysts will remain important to watch.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial...
HEMAB THERAPEUTICS H (COAG) is drawing unusual attention today. Our newswire has captured 1 story on COAG across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 61/100). The most recent driver: "Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition" (GlobeNewswire).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of COAG coverage reads 61/100 over 1 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on COAG: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier COAG move explainers: 2026-08-17